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CORRESPONDENCE
Letters to the Editor
Fractional Flow Reserve–Guided
Intervention of Angiographically
Nonsignificant Coronary Stenoses
We read with interest the recent DEFER (Deferral Versus
Performance of PTCA in Patients Without Documented Ische-
mia) study by Pijls et al. (1) comparing results of percutaneous
coronary intervention (PCI) with medical therapy in patients with
stable coronary artery disease and angiographically intermediate
stenotic lesions. The study demonstrated no beneficial effects of
PCI in stenosis with fractional flow reserve (FFR) 0.75
(performance group) as compared with medical therapy (defer
group) and increased major adverse cardiac events (MACE) in
lesions with FFR 0.75 (reference group) during 5 years of
follow-up.
It is interesting to note the high frequency of coronary artery
bypass grafting (CABG) during 5 years of follow-up in the
reference group (10.4%), especially given the fact that two-thirds
of the patients had single-vessel disease, with normal left ventric-
ular ejection fraction (68  9), and few with diabetes (13%). This
figure is definitely high as compared with that seen in concurrent
studies such as COURAGE (Clinical Outcomes Utilizing Revas-
cularization and Aggressive Drug Evaluation) (2) and MASS II
(Second Medicine, Angioplasty, or Surgery Study) (3), with the
majority of their patients having multivessel coronary artery disease.
Seventy-seven patients (6.7%) in the PCI arm of the COURAGE
study underwent CABG after median 4.6 years, whereas MASS II
reported 9.3% during 5 years of follow-up.
The DEFER study defined myocardial infarction using a 2-fold
elevation of creatinine kinase, which is not a standard definition as
reported by the joint committee of European Society of Cardiol-
ogy/American College of Cardiology (4). Furthermore, the defi-
nition of acute myocardial infarction after PCI requires at least 3
times elevation above the upper limit of the normal (ULN) and
another study reported 5 to 8 times the ULN (5). We believe that
the definition used in the present study significantly increased the
events of myocardial infarction both in hospital and during
follow-up and might have led to increased MACE in the reference
group (FFR 0.75).
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Reply
We do not believe that the rate of coronary artery bypass grafting
in the reference group of the DEFER (Deferral Versus Perfor-
mance of PTCA in Patients Without Documented Ischemia)
study was high compared with that seen in other studies.
Although in the DEFER study the majority of patients had
single-vessel disease, the reference group only consisted of those
patients with proven ischemia (1). This is in contrast to the
COURAGE (Clinical Outcomes Utilizing Revascularization and
Aggressive Drug Evaluation) trial and many other trials. In those
trials (2), patients were classified according to angiographic crite-
ria, and it is well known that a significant number of angiographic
stenoses in those patients is not functionally important (i.e., not
responsible for reversible ischemia) and that from the functional
point of view, angiographic 2- or 3-vessel disease often becomes
1-vessel disease in terms of inducible ischemia (3,4).
In fact, one of the reasons why outcome after medical treatment
was reasonable compared with that seen with percutaneous coro-
nary intervention (PCI) in the COURAGE trial has been the fact
that in the PCI group, intervention was often performed on
relatively mild lesions, many of them most likely not functionally
significant. Performing PCI of such lesions (fractional flow reserve
[FFR] 0.75) creates a negative bias for PCI as demonstrated in
the perform group of the DEFER study. In contrast, also in the
COURAGE trial, PCI of ischemia-related stenosis (equivalent of
FFR 0.75 in a study) was significantly better than medical
treatment.
At the time when the DEFER study was performed (1997 and
1998), no consistent definition of myocardial infarction in enzy-
matic terms existed, and an increase to more than twice the normal
upper limit was often used. Nowadays, we would have taken a
3-fold increase as standardized in the recent guidelines of the
European Society of Cardiology (5). This would not have made
any fundamental difference for the outcome of the study.
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